// changes done below on July 01 2024 // till here on July 01 2024

Leading Companies Optimizing the Cell Culture Media for Cell Therapy Market

Published: October 2023


Driven by the rise in popularity of cell therapies, there is a growth in demand for cell culture media, reagents and surfaces. It is worth mentioning that, amidst the increasing demand for such products, there is a rise in stringency from regulatory authorities to ensure that the quality of raw materials is good. Therefore, to meet the industry needs, cell therapy manufacturers are actively adopting serum free and xeno free products, which are known to reduce the risk of batch-to-batch variability. We analyzed more than 80 industry players that offer more than 450 cell therapy consumable products. In this article, discover top 5 cell culture media providers.


Since the development of the first cell therapy, this therapeutic segment has garnered significant attention from researchers and medical practitioners. This can be attributed to the fact that cell therapies have been demonstrated to possess a vast potential in the treatment of rare disorders, which were previously considered incurable. The popularity of this therapeutic class of products can also be validated from the fact that, since 2019, more than 1,000 clinical trials focused on cell therapies have been initiated. It is also worth mentioning that over 35 cell and gene therapy candidates have already been commercialized, across various geographical locations, till date. 

However, the marketed cell-based therapies are exorbitantly priced. Even though, with the introduction of automation technologies in cell therapy bioprocessing, the cost and time required for development of such products has reduced significantly, there is still a considerable scope of improvement to make these therapies affordable. In this context, it is worth mentioning that consumables, including media, reagents and matrices, currently constitute nearly 25% of the overall cost of cell therapy manufacturing. Optimization of raw materials, by streamlining the production processes, can help mitigate wastage and further reduce the manufacturing cost. Moreover, for commercial applications, it is crucial to obtain consistent outcomes during the manufacturing process. Cell culture media, with chemically defined formulation, provides enhanced consistency for production purposes. 

Roots Analysis has conducted an exhaustive study on Cell Therapy Media, Kits, Reagents and Surfaces Market featuring the current market landscape of current market landscape and the likely future potential of the cell culture media (supplied alone or in kits as a combination with cell growth supplements), cell culture reagents and ECM market, over the forecast period 2023-2035.

Table of Contents

Below, we have listed (in alphabetical order), the top 5 cell culture media providers, based on their product portfolio / capabilities.

Company    Year of Establishment                     Headquarters     Employee Count          
Irvine Scientific 1970 /Irvine-Scientific-headquarters 501-1,000
Lonza 1897 Lonza-headquarters 10,001+
Sartorius 1870 Sartorius-headquarters 10,001+
STEMCELL Technologies 1993 STEMCELL-Technologies-headquarters 1,001-5,000
Thermo Fisher Scientific 1956 Thermo-Fisher-Scientific-headquarters 10,001+

 

Interested in exploring all 450+ Cell Culture Media, Kits, Reagents and Extracellular Matrices available for cell therapy manufacturing?

Through its Proprietary Platform, PRIME-XV Media, Irvine Scientific Offers Cell Culture Media Solutions for Stem Cells

Irvine Scientific - Cell Therapy Media.webp

Irvine Scientific is a US based company that claims to be a global leader in the manufacturing of cell culture media, reagents and medical devices. In June 2018, the firm was acquired by FUJIFILM, with an aim to expand its contract development and manufacturing business, and to accelerate research and development in the field of regenerative medicine. According to the company’s website, it offers a wide range of services, ranging from media optimization to its commercial production.

The following table presents the details on the cell culture media products offered by Irvine Scientific:

Parameter Description
Number of Facility 2
Location of Consumables Manufacturing Facility
  • California, US
  • Japan
Cell Culture Media Compatibility
  • Serum-Free
  • Serum-Free and Xeno-Free
Type of Cell Therapy

The company offers consumable services for the following cell therapies:

  • Dendritic Cell Therapies
  • NK Cell Therapies
  • Stem Cell Therapies
  • T-Cell Therapies 
Application Area
  • Research Use
  • Manufacturing


Recent Initiatives Undertaken by Irvine Scientific:

  • In April 2023, the company announced the expansion of its BalanCD CHO Media Platform portfolio with the addition of two new, chemically defined growth media- BalanCD CHO Perfusion and BalanCD CHO DG44. These new additions extend the platform with specific media designed to support DG44 cell lines and perfusion culture platforms for the commercialization of monoclonal antibodies, recombinant proteins, biosimilars, and other biomolecule-based biotherapeutics.


Lonza Continues to Innovate and Uphold its Vision of Offering Cell Culture Media Solutions with Customizable Grades, as per the Requirements of the Local and International Quality Standards

Lonza - Cell Therapy Media.webp

Lonza is a Swedish company, which claims to be a one-stop solution for its consumers in the healthcare sector. As per the firm’s website, it is engaged in providing innovative healthcare solutions to its clients across the globe. Additionally, it provides a broad range of products, including small molecules, biologics, cell and gene therapies, pharmaceutical APIs and formulations. Further, the firm provides cell and gene therapy solutions that are cGMP compliant, in order to minimize the risks and challenges associated with scaleup and commercialization of these therapies.

The following table presents the details on the cell culture media products offered by Lonza:

Parameter Description
Number of Facility 3
Location of Consumables Manufacturing Facility
  • New Hampshire, US
  • Texas, US
  • Netherlands
Cell Culture Media Compatibility
  • Serum-Free
  • Serum-Free and Xeno-Free
Type of Cell Therapy

The company offers consumable services for the following cell therapies:

  • Dendritic Cell Therapies
  • NK Cell Therapies
  • Stem Cell Therapies
  • T-Cell Therapies 
Application Area
  • Research Use
  • Manufacturing

 

Recent Initiatives Undertaken by Lonza:

  • In May 2023, Lonza launched TheraPEAK® T-VIVO® cell culture medium in order to accelerate cell therapy development1


Sartorius Offers a Wide Range of Innovative Tools and Services, Ranging From Cell Culture Media Development to its Optimization

Sartorius - Cell Therapy Media.webp

Sartorius is a Germany based company that claims to have the required expertise in the domain of life sciences. The firm’s business operations span across two segments, namely bioprocess solutions, lab products and services. Further, it states to provide the aforementioned solutions through its two subsidiaries, namely Sartorius Lab and Sartorius Stedim Biotech.

The following table presents the details on the cell culture media products offered by Sartorius:

Parameter Description
Number of Facility 2
Location of Consumables Manufacturing Facility
  • Germany
  • Puerto Rico
Cell Culture Media Compatibility
  • Serum-Free and Xeno-Free
Type of Cell Therapy

The company offers consumable services for the following cell therapies:

  • NK Cell Therapies
  • Stem Cell Therapies
  • T-Cell Therapies 
Application Area
  • Research Use
  • Manufacturing


Recent Initiatives Undertaken by Sartorius:

  • In September 2023, the company announced the establishment of a new center of excellence for the development and production of quality-critical materials for cell and gene therapies in Freiburg im Breisgau, Germany, through an investment of EUR 140 million2
  • In July 2023, Sartorious completed the acquisition of Polyplus for the total amount of EUR 2.4 billion with an aim to add innovative solutions of Polyplus to its product portfolio3
  • In July 2023, the company announced the opening of its new cell culture media facility based in Puerto Rico in order to supply high-quality, regulatory-friendly powder media for the manufacturing of therapeutic proteins and other modalities.


STEMCELL Technologies Holds the Necessary Expertise in the Field of Cell Therapy Research in order to Ensure Consistent Quality and Reliable Supply of Raw Materials

STEMCELL Technologies - Cell Therapy Media.webp

STEMCELL Technologies is a Canada based company that claims to have the required expertise related to the development of high-quality cell culture media, instruments and auxiliary products, in order to support research across various therapeutic areas, including immunology, oncology and regenerative medicine.  At present, the product portfolio of the company features over 2,500 premium quality products. As per the firm’s website, it has established operations across 25 countries, along with several distribution networks, to with an aim to cater to customers located across the globe.

The following table presents the details on the cell culture media products offered by STEMCELL Technologies:

Parameter Description
Number of Facility 1
Location of Consumables Manufacturing Facility
  • Canada
Cell Culture Media Compatibility
  • Serum-Free
  • Xeno-Free
  • Serum-Free and Xeno-Free
Type of Cell Therapy

The company offers consumable services for the following cell therapies:

  • Dendritic Cell Therapies
  • NK Cell Therapies
  • Stem Cell Therapies
  • T-Cell Therapies 
Application Area
  • Research Use


Recent Initiatives Undertaken by STEMCELL Technologies:

  • In June 2023, STEMCELL Technologies entered into an agreement with PBS Biotech, under which the former is responsible for supplying 3D cell culture media to enable robust scale-up of human pluripotent stem cell cultures in the latter company's single use bioreactor.


By Providing High Quality GMP Compliant Consumables, Thermo Fisher Scientific Strives to Translate the Clinical Cell Therapy Research into Commercial Products

Thermo Fisher Scientific - Cell Therapy Media.webp

Thermo Fisher Scientific is a US based company that offers integrated products / solutions in the domain of life sciences, clinical diagnostics, industrial and applied sciences. Additionally, it provides a complete suite of cell therapy solutions, including ancillary materials, for stem cell research, manufacturing, and clinical trial assistance. It is worth highlighting that the consumables offered by the company have been used in over 200 clinical trials.

The following table presents the details on the cell culture media products offered by Thermo Fisher Scientific:

Parameter Description
Number of Facility 4
Location of Consumables Manufacturing Facility
  • UK (2)
  • Maryland, US
  • Maryland, US
Cell Culture Media Compatibility
  • Serum-Free
  • Xeno-Free
  • Serum-Free and Xeno-Free
Type of Cell Therapy

The company offers consumable services for the following cell therapies:

  • Dendritic Cell Therapies
  • NK Cell Therapies
  • Stem Cell Therapies
  • T-Cell Therapies 
Application Area
  • Research Use
  • Manufacturing


Recent Initiatives Undertaken by Thermo Fisher Scientific:

  • In June 2023, the company launched Gibco™ OncoPro™ Tumoroid Culture Medium Kit, the first commercially available culture medium that is specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications in order to accelerate the development of novel cancer therapies4

What About the Other Cell Culture Media Providers?

The above presentation features top cell culture media providers selected from a pool of over 80 companies offering more than 450 cell therapy consumables that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com

About Author

Jasmeet Bhalla

With an experience of over 4 years with Roots Analysis, Jasmeet is adept at generating useful insights from unstructured / structured datasets. As a senior analyst at Roots Analysis, she has assisted several clients across multiple industry verticals within the healthcare industry. These verticals include contract services, devices / technologies, and drugs / disease indications. Since the findings of the research are aimed at supporting the clients to make thoughtful decisions for their business, she has hands-on experience on competitive landscape assessment, benchmarking, market sizing and forecasting, as well as several quantitative / qualitative / strategic frameworks.

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry